Syracuse, NY – Upstate Medical University has started injecting people with the Covid-19 experimental vaccine as part of a large study by Pfizer’s pharmaceutical company, which will include 30,000 people in the United States, Brazil, Argentina and Germany.
Upstate is one of 62 nationwide research centers participating in the study. Volunteers are sought to participate in the study to evaluate the safety and performance of a potential vaccine.
Four people received the vaccine this morning in Upstate, Dr. Tim Endy, President of Microbiology and Immunology at Upstate.
There are no approved vaccines to prevent Covid-19, which has spread worldwide since the beginning of this year.
Pfizer is developing its potential vaccine with the German company BioNTech. There are many other companies that are racing to come out with the vaccine as the US struggles with the rise in Covid-19 cases.
Modern, a biotechnology company in Massachusetts, began this week with a major clinical trial in the United States and another Covid-19 vaccine.
The federal government has agreed to pay $ 1.95 billion to buy 100 million doses of Pfizer by the end of this year if the study proves safe and effective. The agreement was signed as part of “Operation Warp Speed,” an effort by the Trump administration to accelerate the development and production of vaccines and treatments to combat the new coronavirus.
Anthony Fauci, a top expert on infectious diseases in the federal government, said on Tuesday that he was “cautiously optimistic” that a viable Covid-19 vaccine may be available by the fall.
Pfizer said its potential vaccine had become a strong candidate based on an evaluation of its safety and immune response. The company said in a statement that there were no serious side effects among the 120 people who received the vaccine in the previous study. Mild to moderate side effects of the experimental vaccine include fever, fatigue and chills.
The study at Upstate will be randomized. This means that some participants will receive a placebo and others a potential vaccine. Most study teams will not know which individuals are receiving a placebo or experimental vaccine.
To be eligible to study, individuals must be in good health, between the ages of 18 and 85, and must be able to accept a study of two years’ duration. Volunteers will be required to provide blood samples within two years of vaccine / placebo administration. During the two-year study period, individuals can be seen up to ten times. The two-year time frame of the study is important to assess safety and long-term immune response.
Upstate said, individuals will be compensated for their participation and will not incur any expenses for participating in the study.
Individuals who have tested positive for the Covid-19 in the past cannot participate. Blood tests can show whether the vaccine elicits an immune response in participants who might repel the virus.
During the first two study visits, participants will receive a study vaccine or a placebo injection. During these times, carrier swabs will also be collected for testing on Covid-19. Blood samples will be taken during subsequent study visits.
Seven days after receiving the placebo / study vaccine, participants are required to keep daily records of any specific reactions.
Individuals interested in participating in the study can get more information on tel. Numbers 315-464-9869 or by e-mail email@example.com.
James T. Mulder specializes in health administration. Do you have a news tip? Contact him at (315) 470-2245 or firstname.lastname@example.org